FOR
PRESS
We're on a mission to change the way the world treats weight. With member outcomes as our north star, we're pioneering a new standard of care for obesity treatment.
Our Results
With the only outcomes-based model, we’ve demonstrated the need for our intensive lifestyle intervention wrapped around GLP-1 medications to deliver sustainable metabolic health. Calibrate is committed to the publication of our results as we set a new standard of care for obesity treatment.
0
Years of published Results
0%
weight loss on average
0+
members served
0
research publications presented
in the news
As the obesity drug market grows, digital health companies juggle patients and payers
Employers face soaring demand for obesity care benefits. Virtual care players are jumping in with a slew of offerings
Digital health companies making a long-term play to tackle metabolic health amid hype over $100B weight loss drug market
Employers grapple with the weight loss drug craze
What happens when you stop taking Ozempic?
Hyped weight loss drugs raise supply, equity concerns
Why obesity must be treated as the root of cardiometabolic disease
When my company botched its new app rollout, we learned a critical lesson about how to serve customers
Type 2 diabetes drugs and weight loss: Calibrate's model starts with pharma and builds out
Calibrate CEO on $100M raise for telehealth obesity service
Telehealth startup Calibrate clinches $100M in fresh funding to expand its weight loss platform
Meet the founder using telemedicine to help Americans lose weight
This startup wants to change how Americans think about weight loss
Inside Calibrate, the telehealth newcomer using doctors and coaches to disrupt the $70 billion weight loss industry
Telemedicine startup Calibrate just raised $5.1 million to treat America's forgotten pandemic–obesity and overall poor metabolic health
Recent Announcements
Calibrate Shares Best Real-World Results to Date for Cohort of 11k Members at The Obesity Society’s Annual Conference, Demonstrating 16.2% Weight Loss Sustained at 24 Months
OCTOBER 19, 2023
Metabolic health program combining GLP-1 medication with behavior change publishes annual results demonstrating 15% average weight loss at 12, 18, & 24 months and reversal of diabetes or prediabetes diagnosis in 81% of participants
FEBRUARY 21, 2023
Medically-supervised commercial program delivers nearly 15% weight loss at scale
NOVEMBER 2, 2022
Podcast Appearances
Why obesity is a chronic disease (not a failure of willpower)–featuring Isabelle Kenyon
APRIL 6, 2023
Calibrate launches enterprise product to bring GLP-1 weight loss drugs to payers/employers
NOVEMBER 29. 2022
Isabelle Kenyon, CEO & Founder of Calibrate, on setting a new standard of care for managing metabolic health
MAY 9, 2022
Growing a Health Business Helping over 20,000 Americans with Sustained Weight Loss—Isabelle Kenyon
MAY 4, 2022
Radically transforming the delivery of healthcare, with Isabelle Kenyon & Kim Boyd from Calibrate
MARCH 9, 2022
More questions?
Contact us at press@joincalibrate.com